Nektar Therapeutics Presents Data On Rezpegaldesleukin From Its Phase 2b REZOLVE-A, Phase 2b REZOLVE-AD Trials At European Academy Of Dermatology And Venereology
Benzinga Newsdesk 1 month ago
News
Nektar Therapeutics (Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at the European Academy of Dermatology and
Nektar Therapeutics (Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria in two oral presentation sessions.